MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term...
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.15 | 2.24302711137 | 51.27 | 58.26 | 50.21 | 270896 | 53.33455343 | CS |
4 | -2.58 | -4.69090909091 | 55 | 58.26 | 50.21 | 187104 | 53.38823565 | CS |
12 | 3.01 | 6.09188423396 | 49.41 | 58.26 | 45.24 | 242557 | 50.55034086 | CS |
26 | 13.92 | 36.1558441558 | 38.5 | 58.26 | 37.55 | 287539 | 47.91527027 | CS |
52 | -8.18 | -13.498349835 | 60.6 | 64.98 | 37.55 | 348372 | 48.81018847 | CS |
156 | 40.05 | 323.767178658 | 12.37 | 64.98 | 4.25 | 341685 | 42.85723288 | CS |
260 | 40.05 | 323.767178658 | 12.37 | 64.98 | 4.25 | 341685 | 42.85723288 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約